About High affinity immunoglobulin epsilon receptor subunit beta
High affinity immunoglobulin epsilon receptor subunit beta (MS4A2) is a protein
from Homo sapiens identified by UniProt accession
Q01362, 244 residues long.
MolForge cross-references it against 0 known binders and
60 disease associations.
Target properties
| Protein name | High affinity immunoglobulin epsilon receptor subunit beta |
|---|
| UniProt accession | Q01362 |
|---|
| Gene | MS4A2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 244 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (60)
Diseases linked to this target (Open Targets).
- thyroid gland adenocarcinoma · score 0.18
- bone density · score 0.17
- Alzheimer disease · score 0.12
- leukocyte count · score 0.10
- vitamin B12 measurement · score 0.09
- neutrophil count · score 0.09
- lung adenocarcinoma · score 0.08
- neutrophil immunodeficiency syndrome · score 0.06
- Recurrent infection due to specific granule deficiency · score 0.05
- heel bone mineral density · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q01362-F1 | alphafold | PREDICTED | 74.91 | — |
Amino-acid sequence (244 residues)
MDTESNRRAN LALPQEPSSV PAFEVLEISP QEVSSGRLLK SASSPPLHTW LTVLKKEQEF LGVTQILTAM ICLCFGTVVC SVLDISHIEG DIFSSFKAGY PFWGAIFFSI SGMLSIISER RNATYLVRGS LGANTASSIA GGTGITILII NLKKSLAYIH IHSCQKFFET KCFMASFSTE IVVMMLFLTI LGLGSAVSLT ICGAGEELKG NKVPEDRVYE ELNIYSATYS ELEDPGEMSP PIDL
Explore High affinity immunoglobulin epsilon receptor subunit beta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets